middle.news
How Firebrick Pharma’s $1.4M Placement Fuels Nasodine’s Southeast Asia Expansion
8:37am on Thursday 23rd of October, 2025 AEDT
•
Pharmaceuticals
Read Story
How Firebrick Pharma’s $1.4M Placement Fuels Nasodine’s Southeast Asia Expansion
8:37am on Thursday 23rd of October, 2025 AEDT
Key Points
Appointment of Rick Legleiter as non-executive director
License and distribution deal with Innorini expands Nasodine into four countries
Operating cash costs rose 9% due to manufacturing and regulatory expenses
Successful $1.4 million placement boosts cash reserves to $1.94 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Firebrick Pharma (ASX:FRE)
OPEN ARTICLE